Updated COVID-19 Vaccine’s Impact on Various Patient Outcomes | IDWeek 2024

Researchers addressed the efficacy of COVID-19 vaccines that were approved for 2023-2024, finding that they continue to serve as the clinical standard for staying protected against the virus. The first COVID-19 vaccine approval came in August 2021 for Pfizer-BioNTech’s Comirnaty.¹ Since then, updated vaccines have been necessary to keep the public protected against COVID-19 variants and the increase in cases during the winter seasons.

In posters presented at IDWeek 2024, researchers took a deep dive into COVID-19 vaccines approved for 2023-2024. Aside from exploring overall efficacy of the vaccine for protection against COVID-19, they also addressed its effects on hospitalization rates, post–COVID-19 condition, and fatigue. Furthermore, they researched the effects of 2 types of vaccines: the BNT162b2 COVID-19 vaccination as well as the XBB.1.5 variant.^2-6

Check out more of our IDWeek coverage here.

Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.

References

1. FDA approves first COVID-19 vaccine. News Release. FDA. August 23, 2021. Accessed October 10, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

2. Priddy F, McGhee N, Chalkias S, et al. Six-month safety, durability, and cross-neutralization of the SARS-CoV-2 XBB.1.5-containing vaccine. Presented at: IDWeek 2024; October 16-19, 2024; Los Angeles, CA. Poster P-102.

3. Decuir J, Zhu Y, Johnson C, et al. Updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against COVID-19–associated hospitalization among adults — IVY Network, 20 U.S. States. Presented at: IDWeek 2024; October 16-19, 2024; Los Angeles, CA. Poster P-2069.

4. Yehoshua A, Yarnoff B, Di Fusco M, et al. Public health impact and economic value of an additional dose of Pfizer-BioNTech XBB.1.5-adapted COVID-19 vaccine for older adults in the United States. Presented at: IDWeek 2024; October 16-19, 2024; Los Angeles, CA. Poster P-2047.

5. Di Fusco M, Rudolph A, Lupton LL, et al. Effectiveness of BNT162b2 COVID-19 vaccination against long COVID among older adults: A nationwide study. Presented at: IDWeek 2024; October 16-19, 2024; Los Angeles, CA. Poster P-2060.

6. Six-month trajectory of symptoms of COVID-19 fatigue by age and BNT162b2 COVID-19 vaccination status: A prospective study among symptomatic US adults testing positive for SARS-CoV-2 at a national retail pharmacy. Presented at: IDWeek 2024; October 16-19, 2024; Los Angeles, CA. Poster P-1977.